{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:03:17Z","timestamp":1789675397720,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Institutional Foundation of The First Affiliated Hospital of Xi\u2019an Jiaotong University","award":["No. 2025-QN-25"],"award-info":[{"award-number":["No. 2025-QN-25"]}],"id":[{"id":"https:\/\/ror.org\/02tbvhh96","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10495-026-02435-7","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T12:46:23Z","timestamp":1788698783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lactate-associated H3K18la upregulates RNF166 to promote immune evasion in hepatocellular carcinoma by remodeling c-Jun ubiquitination"],"prefix":"10.1007","volume":"31","author":[{"given":"Bingyi","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"2435_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12072-018-9919-1","volume":"13","author":"T Couri","year":"2019","unstructured":"Couri T, Pillai A (2019) Goals and targets for personalized therapy for HCC. Hepatol Int 13:125\u2013137. https:\/\/doi.org\/10.1007\/s12072-018-9919-1","journal-title":"Hepatol Int"},{"key":"2435_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/13645706.2018.1432489","volume":"27","author":"D Gnutzmann","year":"2018","unstructured":"Gnutzmann D et al (2018) Transvascular therapy of hepatocellular carcinoma (HCC), status and developments. Minim Invasive Ther Allied Technol 27:69\u201380. https:\/\/doi.org\/10.1080\/13645706.2018.1432489","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"2435_CR3","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1111\/cas.16194","volume":"115","author":"MD Wang","year":"2024","unstructured":"Wang MD et al (2024) Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: current status, challenges and opportunities. Cancer Sci 115:2159\u20132169. https:\/\/doi.org\/10.1111\/cas.16194","journal-title":"Cancer Sci"},{"key":"2435_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081949","author":"Y Dong","year":"2021","unstructured":"Dong Y et al (2021) Recent advances and future prospects in immune checkpoint (ICI)-based combination therapy for advanced HCC. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13081949","journal-title":"Cancers (Basel)"},{"key":"2435_CR5","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41571-023-00816-4","volume":"20","author":"TF Greten","year":"2023","unstructured":"Greten TF et al (2023) Biomarkers for immunotherapy of hepatocellular carcinoma. Nat Rev Clin Oncol 20:780\u2013798. https:\/\/doi.org\/10.1038\/s41571-023-00816-4","journal-title":"Nat Rev Clin Oncol"},{"key":"2435_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A et al (2022) Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal 20:44. https:\/\/doi.org\/10.1186\/s12964-022-00854-y","journal-title":"Cell Commun Signal"},{"key":"2435_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/s1470-2045(21)00151-0","volume":"22","author":"PR Galle","year":"2021","unstructured":"Galle PR et al (2021) Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol 22:991\u20131001. https:\/\/doi.org\/10.1016\/s1470-2045(21)00151-0","journal-title":"Lancet Oncol"},{"key":"2435_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01027-5","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L, Luo S, Wu K (2021) Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. https:\/\/doi.org\/10.1186\/s13045-020-01027-5","journal-title":"J Hematol Oncol"},{"key":"2435_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN (2018) Regulation and function of the PD-L1 checkpoint. Immunity 48:434\u2013452. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.014","journal-title":"Immunity"},{"key":"2435_CR10","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1186\/s12967-025-07194-8","volume":"23","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhao Y, Xin Q, Zhang J (2025) The enigma of the RING-UIM E3 ligases: its transformative impact on cancer research. J Transl Med 23:1084. https:\/\/doi.org\/10.1186\/s12967-025-07194-8","journal-title":"J Transl Med"},{"key":"2435_CR11","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.celrep.2016.11.005","volume":"17","author":"RJ Heath","year":"2016","unstructured":"Heath RJ et al (2016) RNF166 determines recruitment of adaptor proteins during antibacterial autophagy. Cell Rep 17:2183\u20132194. https:\/\/doi.org\/10.1016\/j.celrep.2016.11.005","journal-title":"Cell Rep"},{"key":"2435_CR12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41419-020-03145-x","volume":"11","author":"CK Oh","year":"2020","unstructured":"Oh CK et al (2020) RING-finger protein 166 plays a novel pro-apoptotic role in neurotoxin-induced neurodegeneration via ubiquitination of XIAP. Cell Death Dis 11:939. https:\/\/doi.org\/10.1038\/s41419-020-03145-x","journal-title":"Cell Death Dis"},{"key":"2435_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00702-021-02442-9","volume":"129","author":"IY Hwang","year":"2022","unstructured":"Hwang IY, Oh CK, Choi YK, Yun N, Oh YJ (2022) RNF166 plays a dual role for Lys63-linked ubiquitination and sumoylation of its target proteins. J Neural Transm (Vienna) 129:463\u2013475. https:\/\/doi.org\/10.1007\/s00702-021-02442-9","journal-title":"J Neural Transm (Vienna)"},{"key":"2435_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41419-024-06595-9","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y et al (2024) RNF166 promotes colorectal cancer progression by recognizing and destabilizing poly-ADP-ribosylated angiomotins. Cell Death Dis 15:211. https:\/\/doi.org\/10.1038\/s41419-024-06595-9","journal-title":"Cell Death Dis"},{"key":"2435_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-020-01686-9","volume":"39","author":"A Brennan","year":"2020","unstructured":"Brennan A, Leech JT, Kad NM, Mason JM (2020) Selective antagonism of cJun for cancer therapy. J Exp Clin Cancer Res 39:184. https:\/\/doi.org\/10.1186\/s13046-020-01686-9","journal-title":"J Exp Clin Cancer Res"},{"key":"2435_CR16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2024.01.008","volume":"187","author":"G Leuzzi","year":"2024","unstructured":"Leuzzi G et al (2024) SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion. Cell 187:861\u2013881e832. https:\/\/doi.org\/10.1016\/j.cell.2024.01.008","journal-title":"Cell"},{"key":"2435_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s13046-022-02559-z","volume":"41","author":"P Yu","year":"2022","unstructured":"Yu P et al (2022) The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun. J Exp Clin Cancer Res 41:346. https:\/\/doi.org\/10.1186\/s13046-022-02559-z","journal-title":"J Exp Clin Cancer Res"},{"key":"2435_CR18","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.ccell.2024.09.006","volume":"42","author":"H Li","year":"2024","unstructured":"Li H, Sun L, Gao P, Hu H (2024) Lactylation in cancer: current understanding and challenges. Cancer Cell 42:1803\u20131807. https:\/\/doi.org\/10.1016\/j.ccell.2024.09.006","journal-title":"Cancer Cell"},{"key":"2435_CR19","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1017\/erm.2022.42","volume":"25","author":"X Lv","year":"2023","unstructured":"Lv X, Lv Y, Dai X (2023) Lactate, histone lactylation and cancer hallmarks. Expert Rev Mol Med 25:e7. https:\/\/doi.org\/10.1017\/erm.2022.42","journal-title":"Expert Rev Mol Med"},{"key":"2435_CR20","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1158\/0008-5472.Can-23-3513","volume":"84","author":"C Zhang","year":"2024","unstructured":"Zhang C et al (2024) H3K18 Lactylation potentiates immune escape of non-small cell lung cancer. Cancer Res 84:3589\u20133601. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-3513","journal-title":"Cancer Res"},{"key":"2435_CR21","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1136\/gutjnl-2024-334361","volume":"74","author":"J Yang","year":"2025","unstructured":"Yang J et al (2025) Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer. Gut 74:1859\u20131872. https:\/\/doi.org\/10.1136\/gutjnl-2024-334361","journal-title":"Gut"},{"key":"2435_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41392-023-01605-2","volume":"8","author":"ZW Huang","year":"2023","unstructured":"Huang ZW et al (2023) STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. Signal Transduct Target Ther 8:391. https:\/\/doi.org\/10.1038\/s41392-023-01605-2","journal-title":"Signal Transduct Target Ther"},{"key":"2435_CR23","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.cmet.2024.10.019","volume":"36","author":"H Tong","year":"2024","unstructured":"Tong H et al (2024) Dual impacts of serine\/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation. Cell Metab 36:2493\u20132510e2499. https:\/\/doi.org\/10.1016\/j.cmet.2024.10.019","journal-title":"Cell Metab"},{"key":"2435_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","author":"JM Chauvin","year":"2020","unstructured":"Chauvin JM, Zarour HM (2020) TIGIT in cancer immunotherapy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-000957","journal-title":"J Immunother Cancer"},{"key":"2435_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y (2023) Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol 16:101. https:\/\/doi.org\/10.1186\/s13045-023-01499-1","journal-title":"J Hematol Oncol"},{"key":"2435_CR26","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","volume":"30","author":"SO Lim","year":"2016","unstructured":"Lim SO et al (2016) Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 30:925\u2013939. https:\/\/doi.org\/10.1016\/j.ccell.2016.10.010","journal-title":"Cancer Cell"},{"key":"2435_CR27","doi-asserted-by":"publisher","first-page":"e2308045","DOI":"10.1002\/advs.202308045","volume":"11","author":"J Huang","year":"2024","unstructured":"Huang J et al (2024) EZH2 inhibition enhances PD-L1 protein stability through USP22-mediated deubiquitination in colorectal cancer. Adv Sci (Weinh) 11:e2308045. https:\/\/doi.org\/10.1002\/advs.202308045","journal-title":"Adv Sci (Weinh)"},{"key":"2435_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang J et al (2018) Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553:91\u201395. https:\/\/doi.org\/10.1038\/nature25015","journal-title":"Nature"},{"key":"2435_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41418-022-01097-7","volume":"30","author":"K Gao","year":"2023","unstructured":"Gao K et al (2023) SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis. Cell Death Differ 30:475\u2013487. https:\/\/doi.org\/10.1038\/s41418-022-01097-7","journal-title":"Cell Death Differ"},{"key":"2435_CR30","doi-asserted-by":"publisher","first-page":"216861","DOI":"10.1016\/j.canlet.2024.216861","volume":"590","author":"L Wang","year":"2024","unstructured":"Wang L et al (2024) TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma. Cancer Lett 590:216861. https:\/\/doi.org\/10.1016\/j.canlet.2024.216861","journal-title":"Cancer Lett"},{"key":"2435_CR31","doi-asserted-by":"publisher","first-page":"7677","DOI":"10.1038\/s41467-022-35469-x","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q et al (2022) PRDM1\/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells. Nat Commun 13:7677. https:\/\/doi.org\/10.1038\/s41467-022-35469-x","journal-title":"Nat Commun"},{"key":"2435_CR32","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.7150\/ijbs.106690","volume":"21","author":"X Zhou","year":"2025","unstructured":"Zhou X et al (2025) TRIM32 promotes neuronal ferroptosis by enhancing K63-linked ubiquitination and subsequent p62-selective autophagic degradation of GPX4. Int J Biol Sci 21:1259\u20131274. https:\/\/doi.org\/10.7150\/ijbs.106690","journal-title":"Int J Biol Sci"},{"key":"2435_CR33","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41419-023-06222-z","volume":"14","author":"Z Wang","year":"2023","unstructured":"Wang Z et al (2023) The E3 ligase TRIM26 suppresses ferroptosis through catalyzing K63-linked ubiquitination of GPX4 in glioma. Cell Death Dis 14:695. https:\/\/doi.org\/10.1038\/s41419-023-06222-z","journal-title":"Cell Death Dis"},{"key":"2435_CR34","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.7150\/ijbs.122689","volume":"22","author":"C Li","year":"2026","unstructured":"Li C et al (2026) FBXL8 Stabilizes I\u03baB\u03b1 and Negatively Regulated NF-\u03baB activation to suppress pancreatic cancer progression. Int J Biol Sci 22:1461\u20131479. https:\/\/doi.org\/10.7150\/ijbs.122689","journal-title":"Int J Biol Sci"},{"key":"2435_CR35","doi-asserted-by":"publisher","first-page":"117553","DOI":"10.1016\/j.bcp.2025.117553","volume":"243","author":"S Tang","year":"2026","unstructured":"Tang S et al (2026) LDHA facilitates immune escape in bladder cancer through H4K5 lactylation-dependent upregulation of PD-L1. Biochem Pharmacol 243:117553. https:\/\/doi.org\/10.1016\/j.bcp.2025.117553","journal-title":"Biochem Pharmacol"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02435-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02435-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02435-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:09:52Z","timestamp":1789672192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02435-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2435"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02435-7","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"224"}}